Related Experiment Video
Updated: Mar 13, 2026
Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus
Vaishali Gaikwad1, Tejash Gohel1, Shrijeet Panickar1
1Department of Microbiology, Government Medical College and Hospital, Latur, Maharashtra, India.
Introduction:
Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge. To treat this multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA), the only option available is glycopeptides such as vancomycin. However, recently, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus strains have emerged with different resistance mechanism. There are newer drugs in the pipeline against MRSA such as ceftaroline, dalbavancin, oritavancin, and tedizolid; however, very little data are available for their use. Recently, ceftaroline has been approved by the US Food and Drug Administration for the treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia due to MRSA. Hence, we tried to evaluate in vitro activity of ceftaroline against MRSA.
Aim:
The aim of this study was to detect in vitro activity of new cephalosporin, ceftaroline, against MRSA.
Materials And Methods:
Thirty nonduplicate MRSA strains were collected from various clinical samples, and minimum inhibitory concentration (MIC) was detected using ceftaroline E-test strips.
Results:
Twenty-eight MRSA isolates (93.33%) were found to be susceptible to ceftaroline.
Conclusion:
Ceftaroline demonstrated promising potency and coverage against MRSA isolates and can be considered an effective alternative treatment keeping vancomycin and linezolid as a reserved option.
Insights
Ceftaroline shows strong in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). This new cephalosporin is a promising alternative for treating MRSA infections, offering an effective option beyond vancomycin.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Staphylococcus aureus is a significant cause of hospital-acquired and community-acquired infections.
- Increasing antibiotic resistance, particularly multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA), poses a global treatment challenge.
- Vancomycin is a primary treatment for MRSA, but emerging resistance necessitates alternative therapeutic options.
Purpose of the Study:
- To evaluate the in vitro activity of the novel cephalosporin, ceftaroline, against clinical isolates of MRSA.
- To assess ceftaroline's potential as an alternative treatment for MRSA infections.
Main Methods:
- Thirty non-duplicate MRSA strains were isolated from diverse clinical samples.
- Minimum Inhibitory Concentrations (MICs) for ceftaroline were determined using E-test strips.
Main Results:
- Ceftaroline demonstrated susceptibility in 93.33% of the tested MRSA isolates (28 out of 30 strains).
- The in vitro data indicate significant antibacterial activity of ceftaroline against MRSA.
Conclusions:
- Ceftaroline exhibits promising potency and broad coverage against MRSA isolates.
- Ceftaroline represents a viable alternative treatment option for MRSA infections, complementing existing therapies like vancomycin and linezolid.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
11:52Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
